Skip to main content
Triangle logo TriangleGet started

Biopsy Procedure (NCT05136196)

BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study: a one-minute explainerNCT051361961 min

Biopsy Procedure trial for Clinical Stage III Cutaneous Melanoma AJCC v8 (NCT05136196). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with advanced non-uveal melanoma or recurrent/metastatic squamous cancers of the oral cavity, oropharynx, hypopharynx or larynx, progressing during or within 12 weeks after PD-1 treatment. Recurrent head-and-neck disease must lack curative options.

The idea: combine oral cabozantinib, which blocks growth signals, with intravenous nivolumab, which releases an immune brake. Researchers study tumor response and biomarker grouping. Prior anti-VEGF treatment is excluded. Prior checkpoint treatment must last at least six weeks.

This phase 2 study plans 150 patients. SWOG leads; 210 US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.